NasdaqGM:CDTX

Stock Analysis Report

Executive Summary

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.

Risks

  • Cidara Therapeutics has significant price volatility in the past 3 months.

Share Price & News

How has Cidara Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.1%

NasdaqGM:CDTX

-0.2%

US Biotechs

-1.0%

US Market


1 Year Return

-69.2%

NasdaqGM:CDTX

-8.1%

US Biotechs

-0.4%

US Market

CDTX underperformed the Biotechs industry which returned -10% over the past year.

CDTX underperformed the Market in United States of America which returned -1.7% over the past year.


Share holder returns

CDTXIndustryMarket
7 Day3.1%-0.2%-1.0%
30 Day-20.7%-0.2%-3.3%
90 Day-33.7%2.4%0.4%
1 Year-69.2%-69.2%-7.3%-8.1%1.8%-0.4%
3 Year-88.7%-88.7%9.7%5.9%39.4%30.4%
5 Yearn/a7.8%2.8%54.2%37.1%

Price Volatility Vs. Market

How volatile is Cidara Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cidara Therapeutics undervalued based on future cash flows and its price relative to the stock market?

1.13x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Cidara Therapeutics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Cidara Therapeutics to establish if it is available at substantial discount.


Price Based on Earnings

Cidara Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.

Cidara Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Cidara Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

Cidara Therapeutics is good value based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Cidara Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

10.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Cidara Therapeutics is high growth as no revenue estimate data is available.

Cidara Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.

Unable to compare Cidara Therapeutics's revenue growth to the United States of America market average as no estimate data is available.

Unable to compare Cidara Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Cidara Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Cidara Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Cidara Therapeutics performed over the past 5 years?

-28.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Cidara Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Cidara Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Cidara Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Cidara Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Cidara Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Cidara Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Cidara Therapeutics's financial position?


Financial Position Analysis

Cidara Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Cidara Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Cidara Therapeutics's level of debt (31.3%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (3% vs 31.3% today).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 4.8x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Cidara Therapeutics has less than a year of cash runway based on current free cash flow.

Cidara Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 15.8% each year.


Next Steps

Dividend

What is Cidara Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Cidara Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Cidara Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Cidara Therapeutics has not reported any payouts.

Unable to verify if Cidara Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Cidara Therapeutics has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Cidara Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

  • Explore strong dividend paying companies in the pharmaceuticals & biotech industry.

Management

What is the CEO of Cidara Therapeutics's salary, the management and board of directors tenure and is there insider trading?

3.0yrs

Average management tenure


CEO

Jeff Stein (64yo)

5.6yrs

Tenure

US$1,363,737

Compensation

Dr. Jeffrey L. Stein, also known as Jeff, Ph.D., has been the Chief Executive Officer, President and Executive Director of Cidara Therapeutics, Inc. since January 2014. Dr. Stein was Principal Financial Of ...


CEO Compensation Analysis

Jeff's remuneration is higher than average for companies of similar size in United States of America.

Jeff's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.0yrs

Average Tenure

48yo

Average Age

The tenure for the Cidara Therapeutics management team is about average.


Board Age and Tenure

2.9yrs

Average Tenure

64yo

Average Age

The average tenure for the Cidara Therapeutics board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$5,61209 Mar 19
Neil Abdollahian
EntityIndividual
Role
Chief Business Officer
Shares2,300
Max PriceUS$2.44
SellUS$5,71409 Mar 19
Paul Daruwala
EntityIndividual
Role
COO & Chief Commercial Officer
Shares2,240
Max PriceUS$2.55

Ownership Breakdown


Management Team

  • Ken Bartizal (68yo)

    Chief Development Officer

    • Tenure: 5.1yrs
    • Compensation: $335.42k
  • Taylor Sandison (47yo)

    Chief Medical Officer

    • Tenure: 2.9yrs
    • Compensation: $678.49k
  • Paul Daruwala (50yo)

    COO & Chief Commercial Officer

    • Tenure: 1.6yrs
    • Compensation: $662.42k
  • Jim Balkovec

    Senior Vice President of Research

    • Tenure: 4.5yrs
  • Jessica Oien (48yo)

    General Counsel & Secretary

    • Tenure: 0.9yrs
  • Brady Johnson

    Principal Accounting Officer

    • Tenure: 1.0yrs
  • Jamie Levine (48yo)

    Chief Financial Officer

    • Tenure: 0.7yrs
  • Neil Abdollahian (46yo)

    Chief Business Officer

    • Tenure: 3.1yrs
    • Compensation: $945.58k
  • Kevin Forrest (42yo)

    Founder and Chief Strategy Officer

    • Tenure: 3.1yrs
    • Compensation: $613.24k
  • Jeff Stein (64yo)

    President

    • Tenure: 5.6yrs
    • Compensation: $1.36m

Board Members

  • Dan Burgess (57yo)

    Chairman of the Board

    • Tenure: 0.2yrs
    • Compensation: $99.32k
  • Jeff Stein (64yo)

    President

    • Tenure: 5.6yrs
    • Compensation: $1.36m
  • Tim Franson (67yo)

    Director

    • Tenure: 4.4yrs
    • Compensation: $91.35k
  • Ted Schroeder (64yo)

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: $98.07k
  • David Gollaher (69yo)

    Director

    • Tenure: 0.9yrs
    • Compensation: $98.89k
  • Chrysa Mineo (54yo)

    Independent Director

    • Tenure: 1.4yrs
    • Compensation: $179.08k

Company Information

Cidara Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cidara Therapeutics, Inc.
  • Ticker: CDTX
  • Exchange: NasdaqGM
  • Founded: 2012
  • Industry: biotechnology
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$35.869m
  • Shares outstanding: 26.77m
  • Website: Click here

Number of Employees


Location

  • Cidara Therapeutics, Inc.
  • 6310 Nancy Ridge Drive
  • Suite 101
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CDTXNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDApr 2015
20DDB (Deutsche Boerse AG)YesCommon SharesDEEURApr 2015

Biography

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. Its lead produc ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/17 01:03
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.